Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:17:46 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



News for U:ACET from 2023-05-04 to 2024-05-03 - 34 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-30 17:10U:ACETNews ReleaseAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2024-04-22 16:30U:ACETNews ReleaseAdicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
2024-04-08 07:00U:ACETNews ReleaseAdicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
2024-03-28 17:19U:ACETNews ReleaseAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2024-03-19 16:10U:ACETNews ReleaseAdicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
2024-03-11 07:00U:ACETNews ReleaseAdicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
2024-02-29 19:46U:ACETNews ReleaseAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2024-01-31 16:39U:ACETNews ReleaseAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2024-01-25 16:01U:ACETNews ReleaseAdicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters ¢ € ™ Option to Purchase Additional Shares
2024-01-22 23:43U:ACETNews ReleaseAdicet Bio, Inc. Announces Pricing of Public Offering
2024-01-22 16:28U:ACETNews ReleaseAdicet Bio, Inc. Announces Proposed Public Offering
2024-01-04 07:00U:ACETNews ReleaseAdicet Provides Corporate Update and Highlights Strategic Priorities for 2024
2024-01-03 16:01U:ACETNews ReleaseAdicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook
2023-12-29 16:50U:ACETNews ReleaseAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2023-12-10 12:00U:ACETNews ReleaseAdicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting
2023-11-08 16:10U:ACETNews ReleaseAdicet Reports Third Quarter 2023 Financial Results and Provides Business Updates
2023-11-07 07:00U:ACETNews ReleaseAdicet Bio to Present at the 2023 Jefferies London Healthcare Conference
2023-11-02 09:00U:ACETNews ReleaseAdicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting
2023-10-31 18:25U:ACETNews ReleaseAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2023-10-04 12:00U:ACETNews ReleaseAdicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference
2023-09-29 17:24U:ACETNews ReleaseAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2023-09-27 09:00U:ACETNews ReleaseAdicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
2023-08-31 16:35U:ACETNews ReleaseAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2023-08-09 16:15U:ACETNews ReleaseAdicet Reports Second Quarter 2023 Financial Results and Provides Business Updates
2023-08-02 16:00U:ACETNews ReleaseAdicet Bio to Participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference
2023-07-31 16:50U:ACETNews ReleaseAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2023-07-11 08:30U:ACETNews ReleaseAdicet Announces Appointment of Katie Peng to the Board of Directors
2023-06-30 16:51U:ACETNews ReleaseAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2023-06-26 16:00U:ACETNews ReleaseAdicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin ¢ € ™s Lymphoma (NHL)
2023-06-01 07:00U:ACETNews ReleaseAdicet Bio to Participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference
2023-05-31 16:53U:ACETNews ReleaseAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2023-05-18 06:00U:ACETNews ReleaseAdicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
2023-05-09 16:30U:ACETNews ReleaseAdicet Bio to Present at the 2023 JMP Securities Life Sciences Conference
2023-05-09 16:10U:ACETNews ReleaseAdicet Reports First Quarter 2023 Financial Results and Provides Business Updates